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Background: Health-related quality of life (HRQoL) has been shown to predict adverse health 
outcome in the general population.  
Objective: We examined the cross-sectional association between HRQoL and cognitive 
performance at baseline. Next, we explored whether baseline HRQoL predicted 5-year incident 
cognitive decline and dementia; and whether there were gender differences.   
Methods: 19,106 community-dwelling participants from the ASPirin in Reducing Events in 
the Elderly (ASPREE) trial, aged 65–98 years, free of major cognitive impairments, and 
completed the HRQoL 12-item short-form (SF-12) at baseline (2010-2014), were followed 
until June 2017. The physical (PCS) and mental component scores (MCS) of SF-12 were 
calculated. The cognitive tests were assessed at baseline, year 1, 3, 5 and 7 or close-out visit. 
Cognitive decline was defined as >1.5 SD drop from baseline on any of the cognitive tests.  
Dementia was adjudicated according to DSM-IV criteria. Linear and Cox proportional-hazards 
regressions were used to examine the cross-sectional and longitudinal associations 
respectively.  
Results: At baseline, higher PCS and MCS were associated with better cognition. Over a 
median 4.7-year follow-up, higher MCS was associated with a reduced risk of cognitive decline 
and dementia (12% and 15% respectively, per 10-unit increase) and a 10-unit higher PCS was 
associated with a 6% decreased risk of cognitive decline. PCS did not predict dementia 
incidence. Findings were not different by gender.  
Conclusion: Our study found that higher HRQoL, in particular MCS, predicted a reduced risk 
of cognitive decline and dementia over time in community-dwelling older people. 
Keywords: quality of life, health-related quality of life (HRQoL), dementia, cognitive 





Dementia represents a major global health challenge, with nearly 10 million new dementia 
cases diagnosed per year worldwide [1]. The estimated number of people living with dementia 
globally is expected to increase in size from 50 million in 2015 to around 152 million by 2050 
[1]. In addition, cognitive decline and dementia lead to a high direct cost of healthcare services, 
increased indirect costs of unpaid caregiving by family members, and loss in national 
productivity [2]. In 2015, the estimated global cost of dementia was 818 billion USD; it is 
expected to reach 2 trillion USD by 2030 [1]. Cognitive decline and dementia also increase the 
physical, psychological and social burden on caregivers, family and society. Early detection of 
older people at a higher risk of developing dementia or cognitive decline is also associated with 
quality of life [3] and could permit starting preventive interventions before symptom onset.  
Health-related quality of life (HRQoL) is an individual’s perception of their health status and 
includes physical, mental, emotional, and social domains [4]. It assesses the impact of health 
on individuals’ lives and is useful in describing the life experiences of older adults [4, 5]. Self-
reported HRQoL has been shown to predict incident cardiovascular diseases, future 
hospitalization and all-cause mortality in both patient and general populations [6-8]. Hence, 
HRQoL is not only important for well-being, but is also a measure increasingly suggested as 
an effective indicator for health outcomes including all-cause mortality, incident cancer, and 
cardiovascular disease in the primary health setting [7, 9, 10]. However, the relationship 
between HRQoL and cognitive function is complex. Cognitive training interventions have been 
found to be protective against HRQoL decline in older people [11]. On the other hand, 
individuals with poorer HRQoL may be less likely to engage in physical and social activities 
[12], and these are risk factors for cognitive decline. Poorer HRQoL may thus also be a risk 
factor for subsequent dementia. To our knowledge, only one prospective study has investigated 
the relationship between HRQoL and dementia incidence [13]. This study of 1,183 older United 
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States (US) adults followed over an average 4.6 years, reported that higher mental HRQoL 
decreased the incidence of all-cause dementia by 21% [13].  
No subsequent studies have attempted to replicate these findings, nor determine whether 
HRQoL is associated with cognitive decline in the absence of dementia. Further research is 
also required to determine whether these associations differ by gender, given that women are 
at a higher risk of dementia [14] and may have lower HRQoL [15]. This study aims to 
investigate whether the physical (PCS) and mental component scores (MCS) of HRQoL are 
associated with baseline cognitive function; predict the 5-year risk incidence of cognitive 



















MATERIALS AND METHODS 
Study population  
This prospective cohort study used data obtained from a five-year double-blind, randomized 
controlled trial of low dose aspirin as primary prevention in relatively healthy, independent 
community-based older participants from Australia and the US [16]. Between March 2010 and 
December 2014, the ASPirin in Reducing Events in the Elderly (ASPREE) trial recruited a 
total of 19,114 individuals aged 65 years and older (US minorities only), or 70 years and older 
(all others) who were free of major life-limiting diseases likely to be fatal within the next five 
years (e.g. cardiovascular disease, cancer) [16]. Participants also were free of a dementia 
diagnosis and had a Modified Mini-Mental State Examination (3MS) score of ≥78 [16]. In 
Australia, the sample was mainly recruited through partnerships with general practitioners, 
while recruitment in the US was through clinical trial and academic centers [17]. The cohort 
was followed prospectively until June 2017 when randomized study medication ceased. 
ASPREE was undertaken in accordance with the Declaration of Helsinki and approved by 
multiple Institutional Review Boards in Australia and the US. Aspirin was not shown to be 
associated with incident dementia or cognitive decline [18], and thus is not considered further 
in this analysis.  
Determinants: Health-related Quality of Life  
The validated Medical Outcomes Study 12-item short-form (SF-12, version 2) questionnaire 
[19] used to assess HRQoL, was completed by 99.96% of the entire ASPREE cohort at 
baseline.  
Two summary measures ─ the PCS and MCS of the HRQoL ─ were generated using norm-
based scoring methods with a mean of 50 and standard deviation of 10, with higher values 
representing a better HRQoL [20]. The MCS is calculated from a heavier weighting on the SF-
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12 scales of vitality, social functioning, role-emotional and mental health; whereas the PCS has 
a heavier weighting on physical functioning, role-physical, bodily pain and general health [20]. 
Outcome measures  
Assessment of cognitive function  
Trained and accredited ASPREE staff administered the following cognitive function 
assessments at baseline, year 1, year 3, year 5, and year 7 or close-out visit: (a) the Modified 
Mini-Mental State Examination (3MS) [21, 22] to assess global cognition; (b) the Hopkins 
Verbal Learning Test–Revised version (HVLT-R) [23] for delayed recall episodic memory; (c) 
the single letter (F) Controlled Oral Word Association Test (COWAT) [24] to measure 
phonemic verbal fluency; and (d) the Symbol-Digit Modalities Test (SDMT) [25] of 
psychomotor speed.  
Cognitive decline  
Over the course of the study, cognitive decline was defined as a sustained drop of >1.5 SD on 
any of the individual cognitive tests at any follow-up, compared with the baseline score [18]. 
This definition did not include individuals with only a transient decline [18]. Additionally, it 
did not include individuals with a dementia diagnosis (as described below), and can therefore 
be considered a milder form of cognitive impairment than dementia – akin to the concept of 
Cognitive Decline No Dementia [26].  
Incident dementia  
Participants with a suspected dementia diagnosis (dementia trigger) over the follow-up period 
of the trial were defined as individuals with a 3MS score < 78 [27] or a drop of >10.15 points 
on the 3MS compared to their predicted score based on gender, age and education, or a report 
of memory concerns or other cognitive problems, or a medical diagnosis of dementia or 
prescription of acetylcholinesterase inhibitors. These individuals then underwent further 
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standardized cognitive and functional assessment as described previously [18]. Other 
documents gathered, when available, included laboratory test results, brain computed 
tomography (CT) scan or Magnetic Resonance Imaging (MRI) reports, detailed medical 
records and specialist notes.  
The dementia adjudication committee, a panel of neurologists, neuropsychologists and 
geriatricians from Australia and the US, reviewed all available information and adjudicated the 
dementia diagnosis based on the Diagnostic and Statistical Manual for Mental Disorders, 
American Psychiatric Association (DSM-IV) criteria [28]. For confirmed dementia cases, the 
date of a suspected dementia diagnosis was used as the date of dementia incidence.  
Covariates  
Sociodemographic factors considered in the multivariate models included age, gender, years 
of education, living situation and ethno-racial group. Health-related behaviors and clinical 
measures which were considered: smoking status; alcohol consumption; a proxy of physical 
ability – average longest amount of time walking outside home without any rest in the last two 
weeks; hypertension; diabetes; body mass index (BMI); depressive symptom score [29] and 
cognitive performance.  
Statistical analysis  
PCS and MCS were standardized for analyses so that any result was interpreted as the 
association/effect for every 10-unit increase in PCS or MCS.  
Linear regression models were used to examine the cross-sectional association at baseline 
between PCS/MCS and cognitive function. The multivariable models were adjusted for age, 
gender, years of education, living situation, ethno-racial group, smoking status, alcohol 
consumption, average longest amount of time walking outside home without any rest, 
hypertension, diabetes, BMI, and depressive symptoms.  
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Cox proportional-hazards regression models were used to examine the longitudinal 
associations between PCS/MCS and incident dementia, and cognitive decline. Firstly, the 
multivariate Cox models were adjusted for age, gender, years of education, living situation, 
ethno-racial group, smoking status, alcohol consumption, average longest amount of time 
walking outside home without any rest, hypertension, diabetes, BMI, and depressive symptom 
scores. Secondly, we additionally adjusted for baseline cognitive function assessed by HVLT-
R delayed recall, COWAT and SDMT, aiming to control for baseline cognitive status which 
helps minimize reverse causation (whereby low cognitive function could lead to poorer 
HRQoL, and lower baseline cognition is a risk for cognitive decline). 
The possible interaction between PCS/MCS and gender was fitted by including multiplicative 
terms between these variables in the Cox regression models. PCS and MCS were also treated 
in quartiles to plot the crude cumulative incidence hazard function curves. Statistical software 











Of the 19,106 included participants, over half were female (56.4%) and the majority had 12 or 
more years of education (54.8%) (Table 1). The mean and standard deviation of HRQoL and 
cognitive performance scores were 55.7 (7.1) for MCS, 48.3 (8.8) for PCS, 7.7 (2.8) for HVLT-
R, 93.4 (4.6) for 3MS, 12.1 (4.6) for COWAT, and 36.7 (10.1) for SDMT respectively (Table 
1).  
Cross-sectional associations  
Cognitive scores on the 3MS, HVLT-R and SDMT were positively associated with MCS (all 
p-values < 0.001), while SDMT and COWAT were associated with PCS (all p-values < 0.001) 
(Table 2). 
Longitudinal associations  
Over the 4.7-year median follow-up, there were 574 individuals with incident dementia (6.8 
events per 1,000-persons-year), and 2,412 had cognitive decline (39.1 events per 1,000-
persons-year). In multivariate models, a 10-unit higher MCS was associated with a 15% 
decrease in incident dementia risk and a 12% decrease in the risk of cognitive decline (Table 
3, Figure 1 and Supplementary Figure S1). A 10-unit higher PCS was associated with a 6% 
decrease in the risk of cognitive decline after adjustment, including for baseline cognitive 
function (Table 3). The cumulative incidence hazard function curves showed consistent results 
(Supplementary Figure S2). PCS did not predict dementia incidence (Table 3 and 







In this large community sample of relatively healthy older people initially free of dementia, a 
higher HRQoL (both PCS and MCS) predicted a lower risk of cognitive decline, and a higher 
MCS, but not PCS predicted a lower risk of dementia over the 4.7-year median follow-up 
period.  
Our observation that HRQoL (both PCS and MCS) predicted cognitive decline over time, is 
consistent with a prior report that a one-unit higher in overall HRQoL derived from EQ-5D 
was associated with a 47% decrease in the risk of general cognitive decline among 74 
community-dwelling frail older Japanese people with the mean age of 81.6 (8.2) years followed 
for two years [30]. The concordance in findings across two very different samples indicates 
that the association between HRQoL and cognitive decline may be widely generalizable. In 
addition, given our study is the first and largest study investigating this predictive capacity of 
HRQoL on cognitive decline among older people from the community setting, our results bring 
novel findings to the field.  
Our study additionally provides some of the first evidence that MCS can predict future risk of 
dementia. Recently, it was reported for the first time that a 10-unit higher in MCS assessed 
with the SF-36 was associated with a 26% decrease in the risk of incident dementia over an 
average 4.6-year follow-up among 1,183 older Americans [13]. Comparatively, our study 
found that a 10-unit higher in MCS SF-12 was associated with a 15% decrease in the incident 
dementia risk over 4.7-year median follow-up. The lower strength of longitudinal association 
observed in our study may be explained by our inclusion criteria based on which the recruited 
study sample consisted of apparently healthy older adults resulting in a much healthier sample. 
This would have not only lead to a lower incidence of dementia overall, but a sample with less 
chronic disease. It may be expected that the predictive power of HRQoL on dementia is higher 
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in individuals with more comorbidity. Nonetheless, the findings of our study align with the 
only other previous one [13], in demonstrating that that MCS, but not PCS was associated with 
the risk of dementia.  
Indeed, HRQoL is used to assess an individual’s perception (self-rated assessment) of their 
general health, and limitations in everyday activity due to physical and mental ill-health in the 
previous 4 weeks [20]. The MCS calculation consists of a heavier weighting on mental health-
related domains of SF-12 HRQoL such as limitations in usual activities due to emotional 
problems and mental health [20]. MCS and PCS thus assess distinct aspects of an individual’s 
self-rated health and well-being, which could account for the differing associations with 
dementia. While distinct from mental health, the MCS has been shown to be a valid screening 
tool for both depression and anxiety disorders in the general population [31].  Thus, as we 
expected, our finding of evidence in MCS predicted dementia risk reflects a wealth of literature 
demonstrating that midlife or late life depressive symptoms are associated with approximately 
two folds increase in the risk of developing dementia in older people [32, 33].  
The potential pathophysiological mechanisms linking poorer MCS with dementia could 
involve a range of overlapping pathophysiological substrates such as vascular disease, 
neuroinflammatory changes, deficits of nerve growth factors high cortisol levels and amyloid 
accumulation [34]. In brief, neurotransmitter imbalance and hypothalamic-pituitary-adrenal 
axis dysregulation in depression and mental illness may cause increased amyloid precursor 
protein expression, decreased brain-derived neurotrophic factor expression, hippocampal cell 
injury and death, synaptogenesis, neurogenesis, and synaptic plasticity etc. [34, 35]. This in 
turn would lead to amyloid deposition, tau hyperphosphorylation and aggregation, and 
neurodegeneration which are the pathological hallmark of dementia [34, 35]. In addition, sleep 
problems are a common symptom in depression [36], and may be associated with worse MCS. 
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Poor sleep (quality and quantity) has been shown to be associated with amyloid deposition 
[37]. This might be another mechanism helping link poor MCS to an increased risk of dementia.  
Limitations  
Limitations of the study include the relatively short follow-up period (i.e. a median 4.7 years 
follow-up) to identify new dementia cases in a relatively healthy sample, since dementia has a 
long asymptomatic prodromal phase [38]. However, given that our cohort was healthier than 
the respective aging populations, the effect sizes found in our study were perhaps even under-
estimated. However, it remains possible that there were other factors which were not included 
in this analysis, which could have influenced the findings. For example, hearing impairment 
which has been recognized as a risk factor for dementia [39]. 
Strengths  
Strengths of this study include the large community-based cohort of initially healthy 
individuals followed prospectively with rich phenotypic data and rigorous assessment of 
cognitive outcome and dementia diagnosis. Thus, ensuring quality data. Furthermore, our study 
obtained the cognitive decline/dementia status of all ASPREE 19,106 participants who 
completed HRQoL at baseline, with thus no loss to follow-up over a median follow-up of 4.7 
years. Another strength of this study was adjusting for cognitive function at baseline, thus 
helping to minimize potential reverse causation. Indeed, we found that cognition at baseline 
was positively associated with better HRQoL, which aligns with findings from previous cross-
sectional studies [40, 41]. For example, among 5,557 community-dwelling Chinese people 
aged 60 years and older, lower HRQoL derived from European Quality of Life-5 Dimensions 
(EQ-5D) index (which does not differentiate between PCS or MCS) was associated with 
cognitive dysfunction (assessed using the Abbreviated Mental Test) [40]. Similarly, a study 
examining the 83 patients aged 34 to 86 years with head and neck cancer reported that cognitive 
impairment was associated with lower quality of life derived from FACT-Head and Neck 
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Cancer [41]. Our study suggests for the first-time differential associations between HRQoL 
and the underlying domains of cognitive function that each test assesses. For example, global 
cognition and episodic memory are predominantly tasks of general cognitive function, verbal 
learning and episodic memory (respectively) [22, 23], supporting their stronger association 
with their mental well-being. On the other hand, SDMT assesses psychomotor speed, which 
involves processing and motor speed abilities [42], and could account for a stronger 
relationship with both PCS and MCS.  
Clinical implications  
Our finding supports the incorporation of the SF-12 into the routine assessment of Patient-
Reported Outcome Measures (PROMs) of health systems, which could enhance existing 
dementia risk assessment which currently uses only age, gender, blood tests and lengthy 
neuropsychological assessments. Together, this could enable initiation of early preventive 
interventions for people at high risk of cognitive decline and dementia before clinical onset. 
Moreover, the SF-12 comprises 12 questions using plain language, and it takes only 2-3 
minutes to complete [20]. Therefore, the nature of SF-12 reduces both respondent and 
administrative burden [20]. Additionally, given that the SF-12 can predict health outcomes 
such as all-cause mortality and cardiovascular disease in general older people [9, 10, 43], the 
routine use of SF-12 in the health care delivery system can provide other useful information in 
addition to dementia risk prediction. Hence, our novel findings provide evidence in support of 
the decision of the Australian Commission on Safety and Quality in Health Care to incorporate 





In conclusion, this large study provides some of the first evidence that higher HRQoL predicted 
a lower risk of cognitive decline and dementia in relatively healthy older community-dwelling 
people. Our novel findings also support the conclusion of prior research in both patients and 
the general population. Further research is recommended to explore the potential mechanisms 
by which HRQoL affects cognitive impairment and dementia in later life and evaluate whether 
interventions aimed at improving HRQoL also provide cognitive benefits. Moreover, our study 
also indicates the importance of further investigating the potential of interventions which 
improve HRQoL and whether they are effective in reducing the risk of cognitive decline and 
dementia incidence in community-dwelling older people. Further research in this area will be 
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Table 1. Baseline characteristics of participants N = 19,106  
Baseline Characteristics Participants 
 Number (%) or Mean (SD) 
Sociodemographic factors   
Age in years; median (interquartile range) 74 (71.6-77.7) 
Gender   
   Male  8,329 (43.6 %) 
   Female  10,777 (56.4 %) 
Years of Education   
   Under 12 years  8,634 (45.2 %) 
  12 years and above  10,471 (54.8 %) 
Living Situation   
   At home alone  6,249 (32.7 %) 
   With family or others  12,857 (67.3 %)  
Race and Ethnicity   
   White Australian 16,355 (85.6 %) 
   White American  1,088 (5.7 %)  
   Black  900 (4.7 %) 
   Hispanic/Latino; Asiatic; Other a  763 (4.0 %) 
Health-related Behaviours   
Smoking Status   
   Never  10,575 (55.4 %) 
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Baseline Characteristics Participants 
 Number (%) or Mean (SD) 
   Former  7,796 (40.8 %)  
   Current  735 (3.9 %)  
Alcohol Consumption   
   Never / Former  4,468 (23.4 %) 
   Current 14,638 (76.6 %) 
Average longest amount of time walking outside home 
without any rest (last 2 weeks)  
 
   No Walking 839 (4.4 %) 
   <= 15 min/day  2,341 (12.3 %) 
   16 – 30 min/day  4,144 (21.7 %) 
   > 30 min/day  11,741 (61.6 %) 
Clinical Measures   
Hypertension b  
   Yes  14,191 (74.3 %) 
   No  4,915 (25.7 %) 
Diabetes c  
   Yes  2,044 (10.7 %) 
   No 17,062 (89.3 %) 
Body Mass Index (kg/m2) 28.1 (4.7) 
Centre for Epidemiologic Studies Depression Scale (CES-




Baseline Characteristics Participants 
 Number (%) or Mean (SD) 
Health-related quality of life   
Mental Component Scores (MCS) 55.7 (7.1) 
Physical Component Scores (PCS) 48.3 (8.8) 
Cognitive Function Tests   
Hopkins Verbal Learning Test (HVLT) Delayed Recall  7.7 (2.8) 
Modified Mini-Mental State Examination (3MS) 93.4 (4.6) 
Controlled Oral Word Association Test (COWAT) 12.1 (4.6) 
Symbol Digit Modalities Test (SDMT) 36.7 (10.1) 
 
a Other included Hispanic, Latino, Asiatic, Aboriginal and Torres Strait Islander, Native 
Hawaiian, other Pacific Islander, Maori, American Indian, or more than one race; b 
Hypertension = SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or on treatment for high blood 
pressure; c Diabetes mellitus = self-report of diabetes or fasting glucose ≥ 126 mg/dL or on 












Table 2. Association between cognitive function tests with mental (MCS) and physical 




















β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
Crude 0.25 (0.16, 0.34) 0.12 (0.06, 1.18) 0.05 (-0.04, 0.14) 0.82 (0.62, 1.02) 
Adjusted a 0.18 (0.09, 0.28) 0.13 (0.07, 0.19) 0.08 (-0.02, 0.18) 0.69 (0.48, 0.90) 
PCS      
Crude 0.28 (0.21, 0.36) 0.13 (0.08, 0.18) 0.28 (0.21, 0.36) 1.64 (1.47, 1.80) 
Adjusted a -0.01 (-0.08, 0.07) 0.02 (-0.03, 0.07) 0.15 (0.07, 0.23) 0.90 (0.73, 1.06) 
 
Abbreviations: MCS, mental component score; PCS, physical component score. a Adjusted 
for age, gender, education, living situation, ethno-racial group, smoking, alcohol, average 
longest amount of time walking outside home without any rest (last 2 weeks), hypertension, 












Table 3. Hazard ratios for dementia, and cognitive decline by a 10-unit increase in SF-12 




Dementia Cognitive Decline c  








Crude 19,106 574 0.79 (0.71 – 0.88) 17,471 2,412 0.86 (0.81 – 0.90) 
Adjusted a  18,973 571 0.80 (0.70 – 0.90) 17,355 2,390 0.89 (0.84 – 0.94) 
Adjusted b  18,804 564 0.85 (0.76 – 0.96) 17,213 2,363 0.88 (0.83 – 0.94) 
PCS        
Crude 19,106 574 0.92 (0.84 – 1.00) 17,471 2,412 0.87 (0.84 – 0.91) 
Adjusted a  18,973 571 1.03 (0.93 – 1.14) 17,355 2,390 0.95 (0.90 – 0.99) 
Adjusted b  18,804 564 1.06 (0.95 – 1.17) 17,213  2,363 0.94 (0.89 – 0.99) 
 
Abbreviations: MCS, mental component score; PCS, physical component scores. a Adjusted 
for age, gender, education, living situation, ethno-racial group, smoking, alcohol, average 
longest amount of time walking outside home without any rest (last 2 weeks), hypertension, 
diabetes, BMI, and depressive symptom score; b Adjusted for age, gender, education, living 
situation, ethno-racial group, smoking, alcohol, average longest amount of time walking 
outside home without any rest (last 2 weeks), hypertension, diabetes, BMI, depressive 
symptom score and cognitive function at baseline assessed by HVLT-R delayed recall, 









Figure 1. Crude Cumulative incidence of dementia according to the mental component score 















SUPPLEMENTARY MATERIALS  
Table S1. Adjusted hazard ratios for dementia, and cognitive decline by a 10-unit increase in 
SF-12 mental (MCS) and physical component scores (PCS) according to gender  
 
 
Male Female P-value c 
N no. of 
events 
Hazard Ratio a 
(95% CI) 
N no. of 
events 
Hazard Ratio a 
(95% CI) 
Dementia       
    MCS  8,203 268 0.82 (0.68 – 0.98) 10,601 296 0.89 (0.76 – 1.05) 0.92 
    PCS  8,203 268 1.02 (0.88 – 1.19) 10,601 296 1.09 (0.95 – 1.25) 0.62 
Cognitive Decline b        
    MCS  7,531 1,062 0.88 (0.80 – 0.97) 9,682 1,301 0.88 (0.81 – 0.95) 0.88 
    PCS  7,531 1,062 0.97 (0.90 – 1.05) 9,682 1,301 0.92 (0.86 – 0.98) 0.34 
 
Abbreviations: MCS, mental component score; PCS, physical component score. a Adjusted 
for age, education, living situation, ethno-racial group, smoking, alcohol, average longest 
amount of time walking outside home without any rest (last 2 weeks), hypertension, diabetes, 
BMI, depressive symptom score and cognitive function at baseline assessed by HVLT-R 
delayed recall, COWAT and SDMT; b Cognitive decline in individuals without dementia; c P-











Figure S1. Crude Cumulative incidence of cognitive decline according to the mental 
component score (MCS) quartiles.  MCS, Mental component score. Quartile 1 = Lowest, 

















Figure S2. Crude Cumulative incidence of cognitive decline according to the physical 
component score (PCS) quartiles. PCS, Physical component score. Quartile 1 = Lowest, 









Figure S3. Crude Cumulative incidence of dementia according to the physical component 



















Figure S4. Histogram of mental component score (MCS) with quartiles. Q1, Quartile 1; Q2, 


















Figure S5. Histogram of physical component score (PCS) with quartiles. Q1, Quartile 1; Q2, 
Quartile 2; Q3, Quartile 3; Q4, Quartile 4. Quartile 1 = Lowest, Quartile 4 = Highest. 
 
       
 
 
 
